/PRNewswire/ Carmine Therapeutics ("Carmine"), an EVX founded biotech company and emerging leader in non-viral gene therapies, today announced the first.
Carmine Therapeutics appoints Don Haut as CEO
News provided by
Share this article
Share this article
CAMBRIDGE, Mass., May 5, 2021 /PRNewswire/ Carmine Therapeutics, Inc., an emerging leader in gene therapy, today announced that Don Haut, PhD has been appointed as its Chief Executive Officer, and member of the Board of Directors.
Founded and incubated by EVX Ventures, Carmine is developing next-generation, non-viral gene therapies for a broad spectrum of diseases. Based on a proprietary Red Cell Extracellular Vesicle Gene Therapy technology, the REGENT™ technology can overcome the limitations of today s viral-based gene therapies such as immunogenicity, small payload capacity, and manufacturing challenges. As such, Carmine believes its gene therapies have the potential for repeat dosing, large and multiple payload capacity, and improved manufacturing economics.